Skip to main content
Premium Trial:

Request an Annual Quote

Human Genome Sciences And Transgene Sign Gene Therapy Drug Deal

Premium

ROCKVILLE, Md.--Human Genome Sciences here and French biotechnology company Transgene announced in early March a 10-year agreement to accelerate the development of novel gene therapy drugs. HGS will combine its genomics database with Transgene's broad technology platform of gene delivery systems, the companies said.

Transgene will have rights to exclusively license and sublicense up to 10 genes and to develop, manufacture, and commercialize any resulting gene therapy products worldwide.

HGS will take a 10 percent interest in Trangene's equity, and Transgene will pay an initial licensing fee and research funding in an amount equal to the proceeds to Trangene from the HGS purchase. Transgene will pay royalties on future sales and partnering revenues to HGS.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.